iCellate, a privately held Swedish Medtech company, is very happy to announce the closing of the second trench of a total of 15 million SEK second round of funding. iCellate is active in the field of cancer management and uses a simple blood test to detect circulating tumor cells (CTC) in the bloodstream, which is the mechanism that cancer spreads from a primary tumor to form metastases.
Pelle Redare, CEO, comments “With this funding we secure the upcoming commercialization phase, which includes new facilities with a new lab, strengthening of the IP-portfolio and further development of our product offering”.
For further information please contact:
Pelle Redare, CEO, email@example.com
Iohn Ryott, VP Sales & Marketing, firstname.lastname@example.org